AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31270136 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of TKV
Number of subjects: 100
Study 31270136 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of TLV
Number of subjects: 100
Study 29567358 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical VTP‐38543 (0.05%, 0.15%, and 1.0%) applied twice daily for 28 days
Number of subjects: 104
Study 29567358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle control)
Number of subjects: 104
Study 26611780 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (n = 55) ingested daily 9 log10 colony‐forming units of L. salivarius PS2 from approximately week 30 of pregnancy until delivery
Number of subjects: 108
Study 26611780 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 53) received a placebo
Number of subjects: 108
Study 26611780 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (n = 55)
Number of subjects: 108
Study 25202937 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental epidural steroid injection (80 mg of triamcinolone)
Number of subjects: 63
Study 25202937 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 63
Study 22227611 — intervention group
Group type: EXPERIMENTAL
Intervention: Told alcohol (0.4 g/kg ethanol)
Number of subjects: 96
Study 22227611 — intervention group
Group type: COMPARATOR
Intervention: Told placebo (0.0 g/kg ethanol)
Number of subjects: 96
Study 19514827 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored exercise intervention
Number of subjects: 0
Study 19514827 — intervention group
Group type: COMPARATOR
Intervention: Comparison health and wellness intervention
Number of subjects: 0
Study 17959982 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 108
Study 17959982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 15878752 — intervention group
Group type: EXPERIMENTAL
Intervention: GRalpha
Number of subjects: 37
Study 15878752 — intervention group
Group type: EXPERIMENTAL
Intervention: RANK
Number of subjects: 37
Study 15878752 — intervention group
Group type: EXPERIMENTAL
Intervention: CTR
Number of subjects: 37
Study 15878752 — intervention group
Group type: EXPERIMENTAL
Intervention: SID score
Number of subjects: 37
Study 15878752 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of marker expression
Number of subjects: 37
Study 12534378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg
Number of subjects: 108
Study 12534378 — intervention group
Group type: COMPARATOR
Intervention: Rectal diclofenac 50 mg
Number of subjects: 108
Study 11214945 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalin
Number of subjects: 40
Study 11214945 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin
Number of subjects: 40
Study 9120651 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident education (lecture, videotape, individual review)
Number of subjects: 250
Study 9120651 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (pamphlets, discussions)
Number of subjects: 250
Study 9120651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 250
Study 1574244 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose etoposide (1,500-2,500 mg/m2)
Number of subjects: 23
Study 1574244 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose etoposide (2,000 mg/m2 or greater)
Number of subjects: 23
Study 1574244 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose etoposide (1,500 mg/m2)
Number of subjects: 23
Study 2864849 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (mean dosage 142 +/- 100 micrograms/kg/min, range 50 to 300 micrograms/kg/min)
Number of subjects: 12
Study 2864849 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside (mean dose 1.6 +/- 1.3 micrograms/kg/min, range 0.5 to 2.75 micrograms/kg/min)
Number of subjects: 12
Study 2864849 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 12
Study 2864849 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 12
Study 31356409 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based computerized cognitive training (CCT) for 8 weeks
Number of subjects: 46
Study 31356409 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study 29462224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tavaborole 5% topical treatment
Number of subjects: 0
Study 27108476 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate non-surgical periodontal therapy
Number of subjects: 475
Study 27108476 — intervention group
Group type: COMPARATOR
Intervention: Delayed non-surgical periodontal therapy (Control)
Number of subjects: 475
Study 24675394 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard AI treatment plus educational materials (EMs)
Number of subjects: 2758
Study 24675394 — intervention group
Group type: COMPARATOR
Intervention: Standard AI treatment
Number of subjects: 2758
Study 22523314 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle-pulmonary artery shunt (RVPAS)
Number of subjects: 549
Study 22523314 — intervention group
Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 549
Study 20508941 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Number of subjects: 21
Study 20508941 — intervention group
Group type: COMPARATOR
Intervention: Acute exercise (GXT)
Number of subjects: 21
Study 20508941 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 21
Study 18456568 — intervention group
Group type: EXPERIMENTAL
Intervention: rifaximin therapy (1200 mg/day for 10 days)
Number of subjects: 113
Study 18456568 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 113
Study 18456568 — intervention group
Group type: EXPERIMENTAL
Intervention: rifaximin therapy (after placebo)
Number of subjects: 113
Study 18456568 — intervention group
Group type: EXPERIMENTAL
Intervention: rifaximin therapy (for patients with negative BTs)
Number of subjects: 113
Study 16181529 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD Capsules (CHDC)
Number of subjects: 93
Study 16181529 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ID)
Number of subjects: 93
Study 16181529 — intervention group
Group type: COMPARATOR
Intervention: Compound Prescription Danshen Droplet Pills (CPDDP)
Number of subjects: 93
Study 12897564 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic endoscopic evaluation of swallowing
Number of subjects: 8000000
Study 10381807 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 120 mg with placebo
Number of subjects: 17
Study 10381807 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 120 mg with quinidine 100 mg
Number of subjects: 17
Study 10381807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8682138 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg bd
Number of subjects: 608
Study 8682138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR 20 mg bd
Number of subjects: 608
Study 8682138 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atenolol and nifedipine
Number of subjects: 608
Study 8682138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 1986659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) - 20-25 micrograms/kg
Number of subjects: 40
Study 1986659 — intervention group
Group type: COMPARATOR
Intervention: Oral solution of meperidine (1.5 mg/kg), diazepam (0.2 mg/kg), and atropine (0.02 mg/kg)
Number of subjects: 40
Study 1986659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 40
Study 1986659 — intervention group
Group type: COMPARATOR
Intervention: Oral solution of meperidine, diazepam, and atropine
Number of subjects: 40
Study 1986659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 30043997 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation
Number of subjects: 50
Study 30043997 — intervention group
Group type: COMPARATOR
Intervention: Delayed rehabilitation
Number of subjects: 50
Study 27266281 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised magnesium sulphate (MS) 151 mg/dose with ipratropium bromide (IB) 500 µg
Number of subjects: 20
Study 27266281 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ipratropium bromide (IB) 500 µg
Number of subjects: 20
Study 25162691 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up telephone call by a non-health care provider 12 hours after ED visit
Number of subjects: 371
Study 25162691 — intervention group
Group type: COMPARATOR
Intervention: No follow-up call
Number of subjects: 371
Study 21500238 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Binge Eating Disorder (DBT‐BED)
Number of subjects: 101
Study 21500238 — intervention group
Group type: COMPARATOR
Intervention: Active Comparison Group Control (ACGT)
Number of subjects: 101
Study 19732303 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil nightly
Number of subjects: 39
Study 19732303 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil on demand
Number of subjects: 39
Study 19732303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 18574928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 7329
Study 18574928 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 7329
Study 18574928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran and Warfarin
Number of subjects: 7329
Study 15831831 — intervention group
Group type: EXPERIMENTAL
Intervention: Gavestinel
Number of subjects: 571
Study 15831831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study 12435652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligament augmentation device
Number of subjects: 100
Study 12435652 — intervention group
Group type: COMPARATOR
Intervention: No ligament augmentation device (control)
Number of subjects: 100
Study 12435652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 10354252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia severity index (PSI)
Number of subjects: 1024
Study 10354252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalibrated PSI
Number of subjects: 1024
Study 7495203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphapyridine
Number of subjects: 18
Study 7495203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 18
Study 7495203 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 18
Study 7495203 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated controls
Number of subjects: 18
Study 1940965 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP‐choline (1 g)
Number of subjects: 14
Study 1940965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7038950 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram hydrochloride infusions
Number of subjects: 93
Study 7038950 — intervention group
Group type: COMPARATOR
Intervention: Control (no doxapram)
Number of subjects: 93
Study 31048443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal inoculation of genetically modified N. lactamica expressing the meningococcal antigen NadA
Number of subjects: 100
Study 31048443 — intervention group
Group type: COMPARATOR
Intervention: Genetically modified, but wild‐type equivalent control strain
Number of subjects: 100
Study 30049309 — intervention group
Group type: EXPERIMENTAL
Intervention: Etripamil nasal spray (various doses)
Number of subjects: 104
Study 30049309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 30049309 — intervention group
Group type: EXPERIMENTAL
Intervention: Etripamil nasal spray
Number of subjects: 104
Study 30049309 — intervention group
Group type: EXPERIMENTAL
Intervention: Etripamil nasal spray (highest dose)
Number of subjects: 104
Study 27338522 — intervention group
Group type: COMPARATOR
Intervention: Continuous local anesthetic infiltration wound catheter (CLAIWC) for 48 hours
Number of subjects: 60
Study 27338522 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane (TAP) block with ropivacaine
Number of subjects: 60
Study 27338522 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TAP and CLAIWC)
Number of subjects: 60
Study 23833240 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted hysterectomy
Number of subjects: 105
Study 23833240 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 105
Study 22104564 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant interferon alfa‐2b (IFNα‐2b) therapy for 53 weeks
Number of subjects: 268
Study 22104564 — intervention group
Group type: COMPARATOR
Intervention: Observation alone (Control)
Number of subjects: 268
Study 22104564 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant interferon alfa‐2b (IFNα‐2b) therapy
Number of subjects: 268
Study 19156973 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg kg(‐1) rocuronium
Number of subjects: 25
Study 19156973 — intervention group
Group type: COMPARATOR
Intervention: Propofol and sufentanil (anaesthesia)
Number of subjects: 25
Study 17000947 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management trial
Number of subjects: 282
Study 17000947 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for mortality based on 7 independent predictor variables
Number of subjects: 282
Study 17000947 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model
Number of subjects: 282
Study 12594136 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study 12594136 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study 11037045 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy facial stimuli
Number of subjects: 32
Study 11037045 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry facial stimuli
Number of subjects: 32
Study 11037045 — intervention group
Group type: EXPERIMENTAL
Intervention: Left side of the face
Number of subjects: 32
Study 9004102 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 24
Study 9004102 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 24
Study 1458806 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% ketoprofen lysine salt foam
Number of subjects: 0
Study 1458806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6385607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosolvan (60 mg X 2 daily)
Number of subjects: 36
Study 6385607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31291337 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training (CCT)
Number of subjects: 631
Study 28508561 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac 4 h before IVI and topical diclofenac 45 min before IVI
Number of subjects: 74
Study 28508561 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac 45 min before IVI
Number of subjects: 74
Study 28508561 — intervention group
Group type: COMPARATOR
Intervention: Placebo before IVI
Number of subjects: 74
Study 28508561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (oral and topical diclofenac)
Number of subjects: 74
Study 28508561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 25382404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleurotus ostreatus (P.o) and Pleurotus cystidiosus (P.c) at a dose of 50 mg/kg/body weight
Number of subjects: 0
Study 25382404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleurotus ostreatus (P.o) and Pleurotus cystidiosus (P.c) in rats
Number of subjects: 0
Study 25382404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleurotus cystidiosus (P.c) in rats
Number of subjects: 0
Study 25382404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleurotus ostreatus (P.o) and Pleurotus cystidiosus (P.c)
Number of subjects: 0
Study 22871565 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery (RA) graft
Number of subjects: 5
Study 22871565 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein (SV) graft
Number of subjects: 5
Study 21849415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine mouth spray 4 mg
Number of subjects: 45
Study 21849415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine mouth spray 2 mg
Number of subjects: 45
Study 21849415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine mouth spray 1 mg
Number of subjects: 45
Study 21849415 — intervention group
Group type: COMPARATOR
Intervention: Nicotine lozenge 4 mg
Number of subjects: 45
Study 21849415 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum 4 mg
Number of subjects: 45
Study 19131578 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced Exercise (FE)
Number of subjects: 10
Study 19131578 — intervention group
Group type: COMPARATOR
Intervention: Voluntary Exercise (VE)
Number of subjects: 10
Study 16332282 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus self-help
Number of subjects: 96
Study 16332282 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 96
Study 15061344 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference‐Focused Psychotherapy (TFP)
Number of subjects: 90
Study 15061344 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 90
Study 15061344 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Psychotherapy
Number of subjects: 90
Study 11470636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU)
Number of subjects: 68
Study 11470636 — intervention group
Group type: COMPARATOR
Intervention: Nutritional regimen (Control)
Number of subjects: 68
Study 9513843 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrodin-HP
Number of subjects: 0
Study 9513843 — intervention group
Group type: COMPARATOR
Intervention: Pergonal
Number of subjects: 0
Study 8057661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified protocol with high-dose chemotherapy and autologous or allogeneic bone marrow transplantation
Number of subjects: 88
Study 8057661 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of etoposide and cytarabine
Number of subjects: 88
Study 8057661 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment from previous trials
Number of subjects: 88
Study 8057661 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a factor in prognosis
Number of subjects: 88
Study 2923766 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain 0.5% bupivacaine 3 ml
Number of subjects: 40
Study 2923766 — intervention group
Group type: COMPARATOR
Intervention: Plain 0.25% bupivacaine 6 ml
Number of subjects: 40
Study 29984832 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel chocolate-based tablet formulation of midazolam (0.5 mg.kg−1)
Number of subjects: 150
Study 29984832 — intervention group
Group type: COMPARATOR
Intervention: Intravenous solution of midazolam (0.5 mg.kg−1)
Number of subjects: 150
Study 29984832 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel chocolate-based tablet formulation of midazolam
Number of subjects: 150
Study 28723796 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 72
Study 28723796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 26264543 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours of lighted REST
Number of subjects: 30
Study 26264543 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours of unlighted REST
Number of subjects: 30
Study 26264543 — intervention group
Group type: COMPARATOR
Intervention: 6 hours of normal stimulation
Number of subjects: 30
Study 26264543 — intervention group
Group type: COMPARATOR
Intervention: Comparison between lighted REST and unlighted REST
Number of subjects: 30
Study 24011548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 600
Study 24011548 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 600
Study 20842388 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK cage
Number of subjects: 26
Study 20842388 — intervention group
Group type: COMPARATOR
Intervention: PLDLLA cage
Number of subjects: 26
Study 18310694 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (28 knees)
Number of subjects: 71
Study 18310694 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (36 knees)
Number of subjects: 71
Study 16551820 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suture technique
Number of subjects: 139
Study 16551820 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suture technique
Number of subjects: 139
Study 16551820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 139
Study 12970272 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mCi (131)I with rhTSH stimulation after stopping L-T4
Number of subjects: 40
Study 12970272 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mCi (131)I in hypothyroid state after L-T4 withdrawal
Number of subjects: 40
Study 12970272 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving rhTSH without stopping L-T4
Number of subjects: 40
Study 12970272 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 urinary iodine
Number of subjects: 40
Study 12970272 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 urinary iodine
Number of subjects: 40
Study 10965635 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and Ritual Prevention (EX/RP)
Number of subjects: 110
Study 9258101 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative subcutaneous heparin
Number of subjects: 579
Study 9258101 — intervention group
Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 579
Study 7801583 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal body irradiation
Number of subjects: 43